Gut Dysbiosis in Extraintestinal and Intestinal Diseases: Novel Target for Therapeutic Approaches

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Gut Microbiota".

Deadline for manuscript submissions: 15 March 2025 | Viewed by 962

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory of Immunoregulation of Metabolic Disease, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil
Interests: gut microbiota; immune response; obesity; metabolic syndrome; diabetes

Special Issue Information

Dear Colleagues,

The intestinal microbiome maintains a close relationship with the host’s immunity. The gut microbiota interferes in the host’s metabolism, drives the immune response, induces gut hormone production, and reinforces the intestinal barrier. Alterations in the gut microbiota in diseased states are referred to as gut dysbiosis. The concept of gut dysbiosis includes changes in microbiome diversity and/or functional activity with altered bacterial metabolite secretion, particularly short-chain fat acids (SCFAs). Gut microbiota dysbiosis has recently been described in several diseases, including neurological, cardiovascular, metabolic, and autoimmune disorders. Although a causal relationship between gut dysbiosis and diseases remains elusive, recent evidence demonstrates that gut dysbiosis may cause or exacerbate some diseases. Gut dysbiosis might result in the excessive activation of toll-like receptors (TLRs) and a low SCFA production, contributing to the development of extraintestinal or intestinal diseases. It is known that gut dysbiosis is also able to promote molecular mimetism against autoantigens, trigger abnormal immune responses in the gut, favor leaky gut, cause bacterial translocation, and elicit an inflammatory response locally in the gut and other systemic tissues. Novel insights into the modulation of gut microbiota composition, such as prebiotic, probiotic, and postbiotic composition, as a preventive or therapeutic approach have emerged in recent years.

Prof. Dr. Daniela Sartori
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • intestinal microbiome
  • gut microbiota
  • gut dysbiosis
  • host metabolism

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 418 KiB  
Article
Factors for Treatment Failure After Fecal Microbiota Transplantation in Clostridioides difficile Infection
by Soo-Hyun Park, Jung-Hwan Lee, Suhjoon Lee, Jongbeom Shin, Boram Cha, Ji-Taek Hong and Kye Sook Kwon
Microorganisms 2024, 12(12), 2539; https://doi.org/10.3390/microorganisms12122539 - 9 Dec 2024
Viewed by 787
Abstract
Recently, fecal microbiota transplantation (FMT) has been introduced as an effective treatment option for Clostridioides difficile infection (CDI). However, the risk factors associated with FMT treatment failure have not been well demonstrated. Therefore, we aimed to investigate the risk factors of treatment failure [...] Read more.
Recently, fecal microbiota transplantation (FMT) has been introduced as an effective treatment option for Clostridioides difficile infection (CDI). However, the risk factors associated with FMT treatment failure have not been well demonstrated. Therefore, we aimed to investigate the risk factors of treatment failure or recurrence after FMT for CDI. This retrospective study included 124 patients with CDI who underwent FMT at Inha University Hospital between November 2017 and August 2021 and were followed up for 8 weeks after FMT for symptoms of CDI. FMT failure was defined as diarrhea recurrence or a positive stool test. We assessed the risk factors for treatment failure, including comorbidities, antibiotic use pre- and post-FMT, and the number of CDI episodes before FMT. Ninety-three patients (75%) experienced symptom improvement <7 days after FMT, while treatment failure occurred in 40 patients (32.3%). Multivariate analysis revealed that males had a lower symptom improvement rate <7 days after FMT (p = 0.049). Patients using antibiotics after FMT showed a higher rate of recurrence or treatment failure in <8 weeks (p = 0.032). Patients requiring antibiotics after FMT should be considered at higher risk of treatment failure. Careful antibiotic stewardship, particularly minimizing non-essential antibiotic use before and after FMT, may significantly enhance treatment outcomes. Further large-scale prospective studies are warranted to confirm these findings and develop targeted antibiotic management protocols for improving the efficacy of FMT in CDI treatment. Full article
Show Figures

Figure 1

Back to TopTop